Rifasutenizol

DB18981InvestigationalSmall molecule

Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection).

Mechanism: Pharmacologically active on DNA-directed RNA polymerase subunit beta
Curator reviewed
Formula / weight: C₄₈H₆₁N₇O₁₃ · 944.052 g/mol (avg)
Code names: TNP-2198

Resolves to

Compound

UNII2G83RZK9U6CAS1001314-13-1

Structure

InChIKeyGVNMWVKTEANXFY-RRKJDJKOSA-NSMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CCN4C(C)=NC=C4[N+]([O-])=O)CC3)N=C21

Targets

P9WGY9rpoB

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Rifasutenizol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account